Adicet Bio Appoints New Chief Medical Officer

TL;DR

Adicet Bio just hired a new CMO, Dr. Steven T. Rosen, to boost their cancer therapy pipeline.

AI Summary

On September 10, 2024, Adicet Bio, Inc. announced the appointment of Dr. Steven T. Rosen as Chief Medical Officer. Dr. Rosen brings extensive experience in oncology drug development and clinical strategy to Adicet Bio. This appointment is expected to bolster the company's efforts in advancing its pipeline of allogeneic gamma delta T cell therapies.

Why It Matters

The appointment of a new Chief Medical Officer with oncology expertise signals a strategic focus on advancing Adicet Bio's drug pipeline, potentially impacting the development and future success of its therapies.

Risk Assessment

Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and execution, though it also signals a commitment to growth.

Key Numbers

• 001-38359 — Commission File Number (Identifies Adicet Bio's SEC filings.)
• 81-3305277 — IRS Employer Identification No. (Adicet Bio's tax identification number.)

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• Dr. Steven T. Rosen (person) — Newly appointed Chief Medical Officer
• September 10, 2024 (date) — Date of report and earliest event
• 001-38359 (company_id) — Commission File Number
• 81-3305277 (company_id) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20240910.htm (8-K) — 41KB
• 0000950170-24-104915.txt ( ) — 153KB
• acet-20240910.xsd (EX-101.SCH) — 24KB
• acet-20240910_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On September 10, 2024, Adicet Bio, Inc. (the Company or Adicet) announced a strategic prioritization to focus ADI-001 development resources on autoimmune indications. The Company is focusing on advancing the clinical development of ADI-001 in four autoimmune indications, which include lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis, and expects to further expand ADI-001 clinical development into additional autoimmune indications in the near term. Due to this prioritization, patient enrollment in the Phase 1 clinical study of ADI-001 in mantle cell lymphoma (MCL) has been closed, and topline results are reported below. Across all doses, 10 evaluable patients with MCL that were treated with ADI-001 demonstrated an overall response rate (ORR) of 80% (8/10), a complete response (CR) rate of 60% (6/10), with a median duration of complete response of 17.5 months as of August 22, 2024. Patients were heavily pretreated with a median of 3 prior lines of therapy and 30% of patients had progressed on prior CAR T. In the Phase 1 study, ADI-001 demonstrated a favorable safety and tolerability profile, with no occurrences of graft-versus-host disease and low incidence of grade 3 cytokine release syndrome and neurotoxicity that compared favorably to data reported for autologous CD19 CAR T in MCL. Additional translational data from patients enrolled in the Phase 1 clinical study in relapsed/refractory B-cell non-Hodgkin's Lymphoma, which further support the significant potential of ADI-001 in autoimmune indications, will be presented during the 9th Annual CAR-TCR Summit on September 19, 2024 in Boston, MA.

Forward-Looking Statements

Forward-Looking Statements The disclosure under this Item 8.01 contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding reprioritization of the Company's pipeline and expectations for future clinical development activities; the clinical development of ADI-001 in lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis and the Company's expectation to further expand ADI-001 clinical development into additional autoimmune indications in the near term; and the potential safety, tolerability and efficacy of ADI-001 multiple indications. Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disruptions to its preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinic

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADICET BIO, INC. Date: September 10, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR